BMY vs ABBV
BMY and ABBV side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BMYBRISTOL-MYERS SQUIBB COMPANY | ABBVAbbVie Inc. |
|---|---|---|
| Market cap | $128.84B | $510.38B |
| P/E (TTM) | 14.0 | 81.6 |
| P/B | 5.50 | — |
| P/S | 2.7x | 8.3x |
| Dividend yield | 3.92% | 2.28% |
| Revenue | $50.03B(TTM) | $61.16B(TTM) |
| Revenue growth (YoY) | -0.2% | 8.6% |
| Net income | $9.24B(TTM) | $6.31B(TTM) |
| Earnings growth (YoY) | 178.8% | -1.2% |
| EPS, diluted | $4.51(TTM) | $3.54(TTM) |
| EBIT margin | 21.8% | 24.6% |
| ROE | 30.1% | — |
| ROIC | 14.0% | 18.6% |
| Piotroski F | 7/9 | — |
| 1y total return | +41.6% | +35.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BMY vs ABBV
| Metric | BMY | ABBV |
|---|---|---|
| End value | $12.3K | $71.4K |
| Total return | +23.2% | +613.9% |
| CAGR | +2.0% | +20.9% |
| Volatility | 25.4% | 25.8% |
| Sharpe | 0.04 | 0.71 |
| Sortino | 0.06 | 0.99 |
| Max drawdown | -47.7% | -45.1% |
Based on 2600 common trading days, 2016-06-30 → 2026-11-02 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)